Edition:
India

AB Science SA (ABS.PA)

ABS.PA on Paris Stock Exchange

8.17EUR
22 Feb 2018
Change (% chg)

-- (--)
Prev Close
€8.17
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
98,406
52-wk High
€18.07
52-wk Low
€7.53

Select another date:

Thu, Jan 4 2018

BRIEF-Ab Science Says IDMC Recommends Continuation Of masitinib Phase 3 Study With No Requirement To Increase Sample Size

* REG-AB SCIENCE ANNOUNCES THAT BASED ON INTERIM ANALYSIS, IDMC RECOMMENDED THE CONTINUATION OF THE MASITINIB PHASE 3 STUDY IN PROGRESSIVE MULTIPLE SCLEROSIS WITH NO REQUIREMENT TO INCREASE THE SAMPLE SIZE

BRIEF-AB Science announces publication of preclinical data showing that masitinb is capable of counteracting resistance to oncology treatments

* REG-AB SCIENCE ANNOUNCES THE PUBLICATION OF PRECLINICAL DATA SHOWING THAT MASITINB IS CAPABLE OF COUNTERACTING RESISTANCE TO ONCOLOGY TREATMENTS

BRIEF-AB science announces ‍preclinical data showing protective effect of masitinib

* ‍PRECLINICAL DATA SHOWING PROTECTIVE EFFECT OF MASITINIB ON PERIPHERAL NERVOUS SYSTEM IN ALS PUBLISHED IN JOURNAL OF CLINICAL INVESTIGATION INSIGHT​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-AB Science: CHMP adopts negative opinion for Masitinib marketing authorization

* REG-AB SCIENCE ANNOUNCES THAT CHMP ADOPTED A NEGATIVE OPINION FOR MASITINIB MARKETING AUTHORIZATION IN INDOLENT SYSTEMIC MASTOCYTOSIS AFTER REASSESSMENT

BRIEF-AB Science net loss narrows to 13.5 million euros

* NET LOSS OF 13.5MEUR IN FIRST HALF OF 2017, A DECREASE OF 8.4% AS COMPARED WITH FIRST HALF OF 2016 (14.7MEUR )

Select another date: